Lobular Neoplasia of Breast
description
Transcript of Lobular Neoplasia of Breast
Lobular Neoplasia of Breast
Susanna Tam Wai Yin
Kwong Wah Hospital
Joint Hospital Surgical Grand Round 21st April, 2012
Lobular Neoplasia♣ Comprises LCIS & ALH♣ Rare breast lesion
– 3.19 per 100000 women; 0.5-4% in all biopsy» Ellis OI et al. Invasive breast carinoma. In: Tavassoli FA et al. Tumours of the
Breast and Female Genital Organs. Lyon: IARC Press;; 2003:60-62.
– More than doubled in the past 25 yrs» Elsheikh TM et al. Follow-up surgical excision is indicated when breast core
needle biopsyies show atypical lobular hyperplasia or lobular carcinoma in situ: a correlative study of 33 patients with review of the literature. Am J Surg Pathol. 2005;29:534-543.
♣ Clinically important: – risk marker, possible precursor of CA breast
♣ Challenges & controversies in:– Diagnosis & classification– Understanding of its biological behaviour – Appropriate management
Outline
1. Pathology & cytogenetics
2. Clinical Features– Upstaging – Marker of increased risk
3. Management
PATHOLOGY
Lobular Carcinoma in-situ (LCIS)
♣ A monomorphic population of dyshesive cells expanding the terminal duct lobular unit– Acini are completely filled with cells and causing
distension of at least 50% of the acini» Foote FW Jr, Stewart FW (1941) Lobular carcinoma in situ. A
rare form of mammary cancer. Am J Pathol 17:491–496
• Frances P O’Malley. Lobular neoplasia: morphology, biological potential and management in core biopsies. Modern Pathology (2010) 23, S14–S25
Atypical Lobular Neoplasia (ALH)
♣ A less well developed form of LCIS– Acini only partially filled by loosely cohesive cells; <50% of acini
involved if distension present» Page DL, Dupont WD, Rogers LW, et al. Atypical hyperplastic lesions of
the female breast. A long-term follow-up study. Cancer 1985;55:2698–2708.
» Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 1985;312:146–151
ALH
LCIS
• Frances P O’Malley. Lobular neoplasia: morphology, biological potential and management in core biopsies. Modern Pathology (2010) 23, S14–S25
MOLECULAR PATHOLOGY & CYTOGENETICS
•Hanby AM et al. In situ and invasive lobular neoplasia of the breast. Histopathology 2008; 52: 58-66
•O’Malley FP. Lobular neoplasia: morphology, biological potentil and management in core biopsies. Modern Pathology 2010. 23:S14-25.
E-Cadherin
– An adhesion molecule localized at zonula adherens which enchances cellular cohesion
♣ Biallelic loss or down-regulation of E-cadherin gene (CDH1;16q21.1) in LN & ILC– differentiates vs. ductal neoplasms– a/w inherited ILC and diffuse gastric CA
Am J Surg Pathol 2007;31:417–426
CLINICAL FEATURES
Presentation
♣ Clinically occult♣ Often not detectable by MMG♣ Multicentric & bilateral
♣ Incidentally found on core bx
Upstaging on ExcisionPatients & MethodsPatients & Methods ALHALH LCISLCIS
Hussain M et al. Management of lobular carcionma in-stu and atypical hyperplasia of the breast – a review. Eur J Surg Oncol. 2011; 37:279-89
•1229 LN, 789 (64%) excision
•Outcomes of patients without excision rarely reported
19% 32%
Luedtke C et al. Outcomes of prospective excision for classic LCIS and ALH on percutaneous breast core biopsy. Abstract no. 209. US and Canadian Acad of Pathology Annual Meeting; 2011.
•Retrospective review at Memorial Sloan-Kettering Cancer Center (MSKCC)
•82 LN, routine excision
•11 were excluded for synchronous lesions requiring excision or radiologic-pathologic discordance
3%one low grade DCIS & one tubular cancer
0%
Translational Breast Cancer Research Consortium. TBCRC 020
•Prospective study started Nov 2004
•Expected to complete by 2014
In progresshttp://pub.emmes.com/study/bcrc/
Marker of Increased CA Risk
♣ Subsequent CA develops away from original core bx site
♣ Ipsilateral breast slightly > contralateral» Renshaw AA et al. Lobular neoplasia in breast core needle
biopsy specimens is associated with a low risk of ductal carcionma in sit u or invasive carcinoma on subsequent excision. Am J Clin Pathol 2006; 126:310-313.
Relative Risk
♣ ALH: 4-5x; LCIS: 8-10x» Page DL etal. Lobular neoplasia of the breast: higher risk for
subsequent invasiver cancer predicted by more extensive disease. Hum Pathol. 1991;22:1232-9.
♣ Lifetime risk ~1% per year after dx of LCIS– 13% in first 10yrs, 26% after 20yrs, 35% by 35yrs
» Bodian CA et al. Lobular neoplasia. Long term risk of breast cancer and relation to other factors. Cancer. 1996;78:1024-34.
MANAGEMENT
LN Diagnosed by Core Bx
♣ Routine local excision♣ Or only if:
1. Presence of another lesion indicating excision2. Radio-pathological discordance3. Associated mass/distortion4. Indeterminate between ductal and lobular lesion5. Pleomorphic LCIS or other variants– 1-3% missing rate
» Renshaw AA et al. Lobular neoplasia in breast core needle biopsy specimens is associated with a low risk of ductal carcionma in sit u or invasive carcinoma on subsequent excision. Am J Clin Pathol 2006; 126:310-313.
Surveillence
♣ Yearly MMG, P/E Q6-12mth» NCCN Breat Cancer Screening and Diagnois Clinical
Practice Guidelines
♣ Routine MRI screening not supported– No difference in cancer detection rate or trend
towards earlier stage at dx » American Cancer Society guidelines» Oppong BA et al. Recommendations for women with lobular carcinoma in situ
(LCIS). Oncology. Oct 2011: 1051-1058
Chemoprevention♣ Premenopausal: 5yrs of tamoxifen
» NSABP Breast Cancer Prevention Trial (BCPT, P-1) 1998
♣ Postmenopausal: raloxifene» Multiple Outcomes of Raloxifene Evaluation (MORE) study 1999» NSABP Study of Tamoxifen and Raloxifene (STAR, P-2) 2006
♣ Aromatase inhibitors - not recommended» American Society of Clinical Oncology (ASCO)
♣ Highly effective with significant risk– LCIS: 56% ↓; atypical hyperplasia 86% ↓– 3x PE, 2.5x endometrial CA, 1.8x stroke
» Fisher B et al. Tamoxifen for prevention of beast cancer: report of the National Sugical Adjunct Breast and Bowel Project P-1 study. J Natl Cancer Inst. 1998;90:1371-1388.
♣ Not widely embraced `.` risk» Port et al. Patient reluctance toward tamoxifen use for breast cancer
primary prevention. Ann Surg Oncol. 2001;8:580-5.
Bilateral Prophylactic Mastectomy
♣ For a subset of high risk patients (e.g. Strong FHx)
♣ Careful counselling & ample time for consideration needed– risk, benefit, QoL, cosmetic outcome
♣ +/- nipple preservation and/or reconstruction» Oppong BA et al. Recommendations for women with
lobular carcinoma in situ (LCIS). Oncology. Oct 2011: 1051-1058
Conclusion
♣ Understanding of LN is evolving– “carcinoma in-situ” marker of increased CA risk +
non-obligate precursor
♣ Avoid over-treatment– Surveillence is mandatory– If dx by core bx excision only in selected cases– If dx by mammotome / surgical excision re-excision
not needed
♣ Further prospective follow-up & cytogenetic study is warranted
End